Suven Life Sciences Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for FY 2024-25'.
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences has filed its annual Business Responsibility and Sustainability Report for FY 2024-25 with the stock exchanges, as required by SEBI rules. The company is primarily a pharmaceutical research and development firm focused on Central Nervous System (CNS) drug development, with 100% of its turnover from scientific R&D services. Key numbers: revenue of ₹6.65 crore, net worth of ₹799.5 crore, paid-up capital of ₹21.8 crore, and exports contributing 29% of turnover. The company reports no fines, no penalties, no complaints from stakeholders, no workplace safety incidents, and no fatalities during the year. It currently has 138 permanent employees (73% male, 27% female), no CSR spending obligation due to continued losses over the past three years, and 90% of its inputs are sourced sustainably.
This is a routine compliance filing, not a new material event, so it is unlikely to move the stock on its own. However, investors can note the small turnover (₹6.65 crore) against a large net worth, indicating the company is still in a pre-commercial, R&D-heavy phase, and its CNS drug trial outcomes will be the key future value driver.